Almirall grants Kyorin Pharmaceutical exclusive Japanese rights to develop and commercialize aclidinium bromide as monotherapy or in combination with formoterol fumarate for COPD

Almirall S.A.

Spain / Small-Cap Biopharma (<$1 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Kyorin Pharmaceutical Co. Ltd.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

AstraZeneca plc

U.K. / Large-Cap Biopharma (>=$50 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced